Assessing the path forward for Chimerix's brincidofovir in adenovirus
The firestorm over compassionate access that pushed Chimerix Inc. into studying brincidofovir in adenovirus last year already saved the life of Josh Hardy and may now prove to be the company's saving grace as well. After last week's failed Phase III trial in the lead indication of cytomegalovirus (CMV), adenovirus could be brincidofovir's fastest route to market.
Brincidofovir missed the primary endpoint of CMV infection rates in the Phase III SUPPRESS trial to prevent CMV infection in patients undergoing hematopoietic stem cell transplant (HSCT). There also was a higher rate of mortality in the brincidofovir arm compared with placebo, a secondary endpoint.
Chimerix had prioritized CMV infection over adenovirus after completing Phase II trials in both indications. A trial to prevent CMV disease in patients receiving HSCT met its primary endpoint. Another study evaluating preemptive therapy for adenovirus infection in allogeneic HSCT patients missed its primary endpoint but showed a lower rate of mortality.